SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billkirn who wrote (4539)6/22/1998 1:16:00 AM
From: John Metcalf  Read Replies (1) of 6136
 
Slow down, Bill -:) Not much can be said about a Phase I trial, of which the results were just announced.

There were a number of different doses and trial arms, administered to people with advanced cancers. The purpose of the trial was to demonstrate safety, and to gather information on response to the drug at various doses.

Since AG3340 inhibits vascularization of tumors, the response of people whose tumors had grown may not mean much, because they already had blood supply to the tumors. It is possible that AG 3340 will have greater effect earlier in the disease process, as well as in combination with chemotherapeutic agents. Later trials will clarify efficacy, in earlier disease stages, at optimal dosages, in the best combinations. Efficacy conclusions from a Phase I trial are premature.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News